To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Isolated hepatic perfusio… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Journal article
Authors Roger Olofsson
Lars Ny
Malin Sternby Eilard
Magnus Rizell
Christian Cahlin
Ulrika Stierner
Ulf Lönn
Johan Hansson
Ingrid Ljuslinder
Lotta Lundgren
Gustav Ullenhag
Jens Folke Kiilgaard
Jonas A Nilsson
Per Lindnér
Published in Trials
Volume 15
Pages 317
ISSN 1745-6215
Publication year 2014
Published at Institute of Clinical Sciences, Department of Surgery
Institute of Clinical Sciences, Department of Oncology
Sahlgrenska Cancer Center
Pages 317
Language en
Links dx.doi.org/10.1186/1745-6215-15-317
Subject categories Cancer and Oncology, Surgery

Abstract

Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the liver being the most common site for metastases. The median survival for patients with liver metastases is between 6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared with a historic control group consisting of the longest surviving patients in Sweden during the same time period (26 versus 12 months).

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?